COVID-19 Research

COVID-19 Research on Octet Platforms

At Sartorius, we are determined to support the worldwide effort of researchers to find much needed cures and vaccines for the SARS-CoV-2 virus. As part of our commitment, we have compiled links and resources to more information, including how our Octet systems have been used in recent publications in the Resources tab. Since the COVID-19 sequence was first shared in January 2020, Octet system data has been featured in several breakthrough publications related to coronavirus biology, vaccine, and antiviral therapeutic development.

Octet COVID-19 Research

The following summary table provides some important research articles where Octet systems have played a role in elucidating binding kinetics and affinity, neutralization, cross-blocking or titer of COVID-19 virus particles. As new information becomes available, we will update this table and other information on this page to provide the latest information.

Analyte(s)

Immobilized Ligand(s)

Virus species

Assay Focus

Biosensor

Reference

ACE2

Fc-tagged SARS CoV-2 RBD

SARS CoV-2

Cross-reactivity and receptor binding

AHC

[1]

ACE2

SARS-CoV-2 SB SARS-CoV SB

SARS CoV-2

Receptor binding

HIS1K

[2]

mAb, MERS S protein, VHH

SARS CoV-2 S1, SARS CoV-2 RBD

SARS CoV-2

VHH and mAb binding assessment, Epitope binning

AR2G

[3]

Fab, IgG

SARS CoV-2 S protein, SARS CoV-2 RBS

SARS CoV-2

FAB, IgG binding characterization

HIS1K

[4]

ACE2, SARS-CoV RBD

SARS-CoV-specific neutralizing antibodies

SARS CoV-2

Cross-reactivity binding

SA

[5]

Antibodies

Biotin-Recombinant SARS-CoV S1 protein

SARS CoV-2

Neutralization antibody assessment

SA

[6]

FAB, ACE2, SARS S protein

mAb, ACE2

SARS CoV-2

Receptor binding, antibody reactivity, competition assays

AHC, HIS1K

[7]

SARS CoV-2 RBD

Inhibitor Peptide

SARS CoV-2

Peptide inhibitor development

SA

[8]

mAb

S1B and SARS Secto domains

SARS CoV and SARS CoV-2

Antibody reactivity assessment

HIS1K

[9]

SARS CoV-2 RBD, SARS CoV RBD, mAbs, FAB

mAbs, SARS CoV-2 RBD, SARS CoV RBD

SARS CoV and SARS CoV-2

Antibody binding characterization, epitope binning, competition binding

Protein A, HIS2, HIS1K

[10]

Coronavirus S proteins

Biotin-9OAc6SLN

SARS CoV and MERS CoV

Receptor binding

SA

[11]

MERS-5HB fusion inhibitor

Biotin-peptide (MERS-HR2P)

MERS CoV

Protein Inhibitor development

SA

[12]

mAb, MERS S protein

mAb, MERS S protein

MERS CoV

Epitope binning and Receptor binding

SAX, Protein A

[13]

MERS-CoV S

mAbs

MERS CoV

Antibody reactivity measurements, competition assays

AHC, HIS1K

[14]

MERS-CoV NTD, mutants

mAb

MERS CoV

Antibody reactivity measurements

AHC

[15]

MERS S-protein

mAbs

MERS CoV

Antibody reactivity measurements

AHC

[16]

RBD,S1,S2 domains

Vaccine-induced mouse monoclonal IgGs

MERS CoV

Antibody reactivity and epitope binning

AHC, HIS1K

[17]

FABs

MERS-CoV RBD

MERS CoV

Epitope binning

HIS1K

[18]

Octet BLI platforms are helping accelerate COVID-19 research by providing scientists:

  • High-throughput kinetic interaction analysis solutions to select antigenic targets, vaccine and therapeutic candidates fast
  • Fast and flexible platform for antibody epitope characterization and coverage determination
  • Efficient workflows with wide-range of biosensors tailored for vaccine and bio-therapeutic development research
  • Versatile solutions in upstream and downstream vaccine development and manufacturing such as vaccine potency, stability and titer measurements
  • Intuitive easy-to-use data analysis software tools

Binding Kinetics Characterization

Ying et. al. from Fudan University, Shanghai, in collaboration with others at the Wuhan Institute of Virology reportedly assessed the cross-reactivity of anti-SARS CoV antibodies with 2019-nCoV spike protein, considering the relatively high identity of receptor-binding domain (RBD) in 2019-nCoV and SARS-CoV. They reported for the first time, using data obtained on the Octet system, that a SARS-CoV-specific human monoclonal antibody, CR3022, could bind potently with 2019-nCoV RBD (KD of 6.3 nM). Such results are critical to the eventual development of effective antiviral therapeutics and vaccines.

Similar observations were reported by, Joyce et. al. using a high-resolution crystal structure of the SARS-CoV-2 S RBD. Antibodies that were known to interact with SARS-CoV and MERS CoV RBD were tested for SARS-CoV-2 binding activity using an Octet system. Only two antibodies, 240CD and CR3022 out of the pool displayed low nano-molar binding affinities against the SARS-CoV 2 RBD.

Ying et. al. at Fudan University published another article that describes the generation and testing of single domain antibodies targeting SARS-Cov-2 RBD. The panning using SARS-CoV-2 RBD and S1 as antigens resulted in the identification of antibodies targeting five types of neutralizing or non-neutralizing epitopes on SARS-CoV-2 RBD. Eighteen of them were selected for further studies. They bound potently and specifically to the SARS-CoV-2 RBD with subnanomolar to nanomolar affinities as measured by bio-layer interferometry (BLI) and ELISA

Rapid Determination of Virus Binding and Cross-Reactivity

In their article on single domain antibodies targeting SARS-Cov-2 RBD, Ying et. al. tested 18 human single-domain antibodies in competition binding assays using the Octet system and found that they could be divided into three competition groups (group A, B or C) that did not show any competition with each other.

Read the Publication

Insights Into COVID-19 Binding Epitopes

The Octet platform technology is helping scientists around the world learn more about the recent Coronavirus (COVID-19) outbreak. In this flyer we highlight two of the many cases where researchers are using the Octet system to understand the virus's binding mechanisms as a first step in the development of a vaccine.

Download the Flyer

A Fast and High Precision Influenza Vaccine Potency Assay

A fast and accurate determination of vaccine titer during manufacturing is important in understanding vaccine development process performance, and for correctly scaling each process step. The Octet platform combines the high-throughput characteristics of a 96-well or 384-well plate format with improvements in precision and reproducibility and is derived from a simpler and more direct vaccine/antigen–antibody binding measurement method. They provide process development groups with a robust and easy to use alternative to the SRID method. The Octet platform reduces the assay time from days to just a few hours for a 96-well plate of samples.

Download Application Note

Aptamer Group Utilizes Octet Red384 for Accurate Results

The last few months of research has highlighted the S1 protein of SARS CoV-2 as a lead target for therapeutics. A team of Aptamer Group successfully isolated a monoclonal aptamer capable of selectively binding the S1 protein of SARS CoV-2 spike. They used the Octet Red384 system to test the aptamer against SARS CoV-2 and related viruses and also to identify aptamers that bound the protein at different sites.

Explore the RED384

Global COVID-19 Research

Global research on Covid-19 gathered by the World Health Organization (WHO) and updated daily. - WHO COVID-19 Literature

The Allen Institute for AI has partnered with leading research groups to prepare and distribute the COVID-19 Open Research Dataset (CORD-19), a free resource of over 52,000 scholarly articles, including over 41,000 with full text, about COVID-19 and the coronavirus family of viruses for use by the global research community. Online, full text search of the database can be accessed at the link below. A search of publications referencing use of Octet products in virus research can also be performed. - AI Database

A curated list of open funding calls and other support for researchers, non-profit organizations, and commercial organizations, specifically for COVID-19 and coronavirus-related research is maintained and updated daily. - Funding Monitor

The National Institutes of Health (NIH) lists all coronavirus related funding opportunities. - NIH Funding

Related Resources

Influenza Vaccine Titre Determination Bio-Layer Interferometry (BLI)

Fast, accurate determination of vaccine titre during influenza vaccine manufacture is important in understanding process performance and...

Download Poster

Cross Competition or Epitope Binning Assays on Octet HTX system

Epitope binning through cross competition assays is a powerful tool in evaluating functional diversity in antibody clones.

Read Application Note

A Fast and High Precision Influenza Vaccine Potency Assay

Mall molecule and peptide therapeutic drugs are highly sought after in most areas of disease research due to their desirable pharmacological...

Read Application Note

Octet Potency Assay: Development, Qualification and Validation...

In this application note, we discuss the strategies for the development and validation of a potency assay using Octet® systems. We have...

Read Application Note

Recent Insights Into COVID-19 Binding Epitopes

The novel coronavirus, COVID-19, has been declared a pandemic by the world health organization (WHO). As it spreads, researchers are mobilizing...

Download Flyer

Understanding COVID-19 Vaccine and Therapeutic Development Research

Studying antibodies generated from Covid-19 infections and vaccines can provide invaluableinformation towards therapeutic antibody development...

Download Infographic
Explore GxP Applications

Related Content

Biologics Characterization Tools

Explore More

Octet System Service and Support

Explore More

Octet System Highlight Resources

Explore More